Objective: To investigate the curative effect of Deanxit combined with Shuganjieyu capsule on the treatment of refractory gastroesophageal reflux disease. Methods: A total of 125 patients with refractory gastroesophageal reflux disease who had failed in standard lansolazole capsule treatment in the Department of Gastroenterology, First People's Hospital of Neijiang were selected. According to the symptom scores and mood scores of gastroesophageal reflux disease, patients were randomly and double-blindly divided into five groups. Group A(Lansoprazole Capsules + Mosapride Citrate + Deanxit), B(Lansoprazole Capsules + Mosapride Citrate + Shuganjieyu capsule), C(Lansoprazole Capsules + Mosapride Citrate+ Deanxit + Shuganjieyu capsule) and D(Deanxit) groups are study groups, the other was control group (Lansoprazole Capsules + Mosapride Citrate). The scores of symptoms and mood were compared after 4 weeks and 8 weeks of treatment. Results: The clinical symptoms score, HAMA and HAMD scores were significantly lower in the all study groups in comparison to the control group after 4 weeks and 8 weeks therapy. The clinical symptoms score, HAMA and HAMD scores in group C were significantly lower than those in group A and B (P<0.05), while the difference between group A and B was not statistically significant(P>0.05). The HAMA and HAMD scores of group D were significantly higher than those of group A, B, C and control group, and the differences were statistically significant (P<0.05). The total effective rate of study groups were significantly higher than those of the control group, and the difference was statistically significant (P<0.05). The total effective rate of group C was significantly higher than that of group A and B (χ(2)=6.47, P<0.05). The total effective rate of group A at the end of the 8th week was significantly higher than that of group B (χ(2)=6.52, P<0.05). The total effective rate of group D at the end of the 4th and 8th week was significantly lower than those of the group A, B, C and control group, the difference was statistically significant (χ(2)=5.85, P<0.05). Conclusions: Deanxit combined with Shuganjieyu capsule is significantly effective in treatment of refractory gastroesophageal reflux disease, which can effectively improve the total treatment efficiency, reduce the symptom scores and mood scores of gastroesophageal reflux disease patients.
目的： 探讨氟哌噻吨美利曲辛(黛力新)联合舒肝解郁胶囊治疗难治性胃食管反流病的疗效。 方法： 选取内江市第一人民医院消化内科接诊的经过标准兰索拉唑胶囊治疗效果欠佳的难治性胃食管反流病患者125例，评估患者胃食管反流病症状评分和情绪障碍评分后，随机双盲分为研究组A、B、C、D和对照组。A、B、C组和对照组用兰索拉唑胶囊＋枸橼酸莫沙比利；A组＋黛力新，B组＋舒肝解郁胶囊，C组＋黛力新＋舒肝解郁胶囊；D组单用黛力新。比较各组患者治疗4周、8周后胃食管反流病症状及情绪障碍评分，并进行疗效评价。 结果： 研究组各组在治疗第4周和第8周末的症状评分、汉密尔顿焦虑(HAMA)及汉密尔顿抑郁(HAMD)评分均显著低于对照组(P<0.05)，且C组临床症状评分、HAMA及HAMD评分显著低于A组、B组(P<0.05)，而A组与B组比较差异无统计学意义(P>0.05)，D组的HAMA及HAMD评分均显著高于研究组A、B、C和对照组，各组间比较差异均有统计学意义(均P<0.05)。研究组各组的总有效率明显高于对照组，差异有统计学意义(P<0.05)，且C组总有效率均显著高于A组和B组(χ(2)＝6.47，P<0.05)，A组8周末总有效率显著高于B组(χ(2)＝6.52，P<0.05)，D组4周、8周末总有效率均显著低于各研究组和对照组，差异均有统计学意义(χ(2)＝5.85，P<0.05)。 结论： 黛力新联合舒肝解郁胶囊治疗难治性胃食管反流病疗效显著，有效提高患者治疗的总有效率，降低胃食管反流病症状评分及情绪障碍评分。.
Keywords: Deanxit; Gastroesophageal reflux; Reflux, stomach; Shuganjieyu capsule.